ATLANTA, November 10 /PRNewswire/ --

- AMD Patients Treated with POT-4 Demonstrate No Adverse Toxic Effects

Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), presented Phase I data last week during the Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) Annual Meeting in Atlanta, GA. The data was from the ASaP (Assessment of Safety of Intravitreal POT-4 Therapy for Patients with Neovascular Age-Related Macular Degeneration) clinical trial for the company's leading drug candidate, POT-4, which is being developed for the treatment of AMD.

SAN JOSE, California, November 10 /PRNewswire/ --

- Supermicro Cost-effective Personal Supercomputer in Volume Production

Super Micro Computer, Inc. (Nasdaq: SMCI), a leader in application-optimized, high performance server solutions, today announced the addition of the world's most affordable personal supercomputer to its SuperBlade(R) family. Supermicro's new 10-blade server system based on the SBI-7125C-T3 blade provides the industry's most cost-effective blade solution, while also being the greenest personal supercomputer and office computing solution. Based on Supermicro's Server Building Block Solutions(R) architecture, the SBI-7125C-T3 can also be optimized for 14-blade configurations which are ideal for HPC and datacenter applications.

NEW YORK, November 10 /PRNewswire/ --

Liquidnet, the global institutional marketplace, today announced October trading volume for U.S. equities and trading value for international equities. Average daily U.S. natural liquidity was a company record.

Total U.S. trading volume in shares(1) 2,299,641,350 Total trading days 23 Average daily trading volume in shares 99,984,407 Average daily natural liquidity 2,982,495,501 Average execution size in shares(2) 59,007 Total international principal traded in $USD $8,771,289,181

LONDON, November 10 /PRNewswire/ --

CPhI conferences are delighted to announce the addition of a one day briefing on Successfully Sourcing from India and China to the 2008 Pharma conference line-up. This one day event is being held on the 10th December 2008 at the Marriott Hotel, Frankfurt and is already proving to be another hugely successful event from CPhI Worldwide.

Pharma sourcing from India China has seen a rapid rise in recent years with pharmaceutical companies looking to emerging market 'hotspots' to remain competitive in an increasingly price sensitive market. However, sourcing from these new markets comes with potentially catastrophic consequences if product quality and IP rights are compromised.

MUNICH, Germany, November 10 /PRNewswire/ --

- XtremeESD(TM) Protection, EMI Filtering, HDMI(TM) 1.3 and other Interface Protection Solutions Featured

California Micro Devices (Nasdaq: CAMD) will be showcasing its broad range of protection solutions, including devices for electrostatic discharge (ESD) protection and electromagnetic interference (EMI) filtering at Electronica 2008 in Munich from November 11 through 14. These solutions are well suited to a wide range of applications, such as embedded and industrial computing, and consumer electronics.

The XtremeESD Family

NEW YORK, November 10 /PRNewswire/ -- Asset Control, a world-wide leader in financial data management solutions, today announced that WestLB AG, a European commercial bank with headquarters in North Rhine-Westphalia, Germany, has implemented Asset Control's AC Plus financial and reference data management software. AC Plus supports the bank's back-office operations and day-to-day user requirements across its businesses worldwide.

LONDON, November 10 /PRNewswire/ --

- MrTedTalentLink(TM) Version 2.8 Provides Customers With Improved Forms, Flexibility and Technology to Attract, Recruit and Retain Top Talent

MrTed, the leading global provider of Talent Acquisition Solutions, today announced the general availability of MrTedTalentLink(TM) latest version 2.8, its flagship Talent Acquisition Solution, which enables companies of all sizes worldwide to optimise the process of acquiring and deploying talent. (http://www.mrted.com)

LAUSANNE, Switzerland, November 10 /PRNewswire/ --

- Gene Signal International, a Biotech Company Registered in Switzerland, Will Move its Headquarters to the EPFL, in Lausanne, - Gene Signal is Addressing Various Issues Related to Neovascularisation, - Gene Signal is Working on a Portfolio of Ophthalmologic Indications, With One Now in Phase III Trials - Gene Signal Will Present its Interim Results at the Annual Meeting of the American Academy of Ophtalmologist in Atlanta, USA, the Largest Scientific Convention in this Field

Gene Signal, a biotech company registered in Switzerland, is currently starting the Phase III study of GS-101, its most advanced therapeutic ophthalmic solution, for the prevention of corneal graft rejection.

NAGOYA, Japan, November 10 /PRNewswire/ --

- He will play a vital role in Menicon's expansion in the world's contact lens market.

Menicon Co., Ltd. announced the appointment of Jonathan Jacobson as General Manager, Global Business Strategies Operations, effective November 10. Jacobson joined Menicon after serving at Bausch Lomb for 23 years. During this time, Jacobson held many different executive positions including Director of Marketing, Director of International Sales, and Director of International Business for Polymer Technology Corporation. He also acted as Director of GP Business for Bausch Lomb in Europe. For the last 8 years, Jacobson had been the Director of Global GP Business for Bausch Lomb.

CAMBRIDGE, England, November 10 /PRNewswire/ --

- (Stem Cell Sciences, SCS, the Company)

Stem Cell Sciences plc (AIM:STEM, ASX:STC), a company focused on the commercialisation of stem cells and stem cell technologies, announces that it has entered into an agreement with CHDI Foundation, Inc., to support the standardisation of CHDI's novel mouse embryonic stem (ES) cell lines. CHDI is a US non-profit organisation pursuing treatments for Huntington's disease (HD). The cell lines have been produced over a period of several years under varying conditions, and conversion to a standard methodology is expected to facilitate their use in HD-related research towards the development of new HD drugs and diagnostics.